172 related articles for article (PubMed ID: 35066710)
1. Detection of hepatitis C virus (HCV) RNA in the peripheral blood mononuclear cells of HCV-infected patients following sustained virologic response.
Khattab MA; Zakaria Y; Sadek E; Abd El Fatah AS; Fouad M; Khattab M; Moness HM; Adel NM; Ahmed E
Clin Exp Med; 2023 Feb; 23(1):131-140. PubMed ID: 35066710
[TBL] [Abstract][Full Text] [Related]
2. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR.
Frías M; Rivero-Juárez A; Téllez F; Palacios R; Jiménez-Arranz Á; Pineda JA; Merino D; Gómez-Vidal MA; Pérez-Camacho I; Camacho Á; Rivero A
Sci Rep; 2019 Aug; 9(1):12507. PubMed ID: 31467339
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.
Yousif MM; Elsadek Fakhr A; Morad EA; Kelani H; Hamed EF; Elsadek HM; Zahran MH; Fahmy Afify A; Ismail WA; Elagrody AI; Ibrahim NF; Amer FA; Zaki AM; Sadek AMEM; Shendi AM; Emad G; Farrag HA
Infez Med; 2018 Sep; 26(3):237-243. PubMed ID: 30246766
[TBL] [Abstract][Full Text] [Related]
5. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
[TBL] [Abstract][Full Text] [Related]
6. Occult hepatitis C virus infection in hemodialysis patients who achieved a sustained virological response to directly acting antiviral drugs: is it a concern?
Naguib H; Abouelnaga SF; Elsayed MM
Int Urol Nephrol; 2024 Jan; 56(1):217-222. PubMed ID: 37209238
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
Abd Alla MDA; El Awady MK; Dawood RM; Elhawary MA; Al-Azhari SS; Galal AGM
Arch Virol; 2018 Oct; 163(10):2765-2774. PubMed ID: 29971486
[TBL] [Abstract][Full Text] [Related]
8. Reverse inflammaging: Long-term effects of HCV cure on biological age.
Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
[TBL] [Abstract][Full Text] [Related]
9. Occult hepatitis C infection identified in injection drug users with direct antiviral agents therapy and spontaneous resolution of hepatitis C virus infection.
Silva E; Marques S; Leal B; Canhão B; Madaleno J; Simão A; Carvalho A
Virus Res; 2023 May; 329():199104. PubMed ID: 37003528
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
[TBL] [Abstract][Full Text] [Related]
11. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
Liu CH; Chang YP; Lee JY; Chen CY; Kao WY; Lin CL; Yang SS; Shih YL; Peng CY; Lee FJ; Tsai MC; Huang SC; Su TH; Tseng TC; Liu CJ; Chen PJ; Kao JH
J Med Virol; 2024 May; 96(5):e29675. PubMed ID: 38746997
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C viral RNA in blood mononuclear cells of patients treated with directly acting antivirals.
Kamhawy A; Ahmed Said ZN; Abdelhamid SE; El-Sayed M; Eletreby R; Garem HE; El Kassas M; Esmat G
Arab J Gastroenterol; 2021 Jun; 22(2):158-163. PubMed ID: 33820724
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells.
Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Praena-Fernández JM; Márquez-Galán JL; Núñez-Roldán A; Aguilar-Reina J
Liver Int; 2014 Jul; 34(6):e80-8. PubMed ID: 24127783
[TBL] [Abstract][Full Text] [Related]
14. No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.
Del Bello A; Abravanel F; Alric L; Lavayssiere L; Lhomme S; Bellière J; Izopet J; Kamar N
Transpl Infect Dis; 2019 Aug; 21(4):e13093. PubMed ID: 30972874
[TBL] [Abstract][Full Text] [Related]
15. Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Inglot M; Pawlowski T; Szymczak A; Malyszczak K; Zalewska M; Radkowski M
Postepy Hig Med Dosw (Online); 2013 Mar; 67():186-91. PubMed ID: 23619217
[TBL] [Abstract][Full Text] [Related]
16. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal.
Burgui C; San Miguel R; Goñi-Esarte S; Juanbeltz R; Úriz-Otano JI; Reparaz J; Sarobe M; Zozaya JM; Castilla J
Postgrad Med; 2023 May; 135(4):352-360. PubMed ID: 36305320
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
[TBL] [Abstract][Full Text] [Related]
20. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
